BlackRock Advisors’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

BlackRock Advisors’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$16K	Hold	71	–	–	﹤0.01%	3501
2016 Q3	$17K	Hold	71	–	–	﹤0.01%	3488
2016 Q2	$14K	Hold	71	–	–	﹤0.01%	3523
2016 Q1	$30K	Hold	71	–	–	﹤0.01%	3328
2015 Q4	$27K	Hold	71	–	–	﹤0.01%	3409
2015 Q3	$19K	Hold	71	–	–	﹤0.01%	3531
2015 Q2	$21K	Buy	71 +29	+69%	+$8.76K	﹤0.01%	3501
2015 Q1	$12K	Hold	42	–	–	﹤0.01%	3520
2014 Q4	$18K	Buy	+42	New	+$13.3K	﹤0.01%	3534

Other funds holding DMK

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

LCM

Leisure Capital Management Costa Mesa, California $320M AUM 39.11% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SGS

Sterling Global Strategies Carlsbad, California $18M AUM 11.58% 1-Year Est. Return

BlackRock Advisors's DMK Position: Q4 2016 in Review

BlackRock Advisors held its DMK Pharmaceuticals Corporation Common Stock (DMK) position steady in Q4 2016 at 71 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #3501.

BlackRock Advisors first reported a position in DMK in Q4 2014 and has held it in 9 quarters since. The position peaked at $30K in Q1 2016. 35 funds tracked by Wall St. Rank hold DMK as of Q4 2016.

BlackRock Advisors held 71 shares of DMK Pharmaceuticals Corporation Common Stock worth $16K as of Q4 2016.
BlackRock Advisors left its DMK Pharmaceuticals Corporation Common Stock share count unchanged in Q4 2016.
DMK Pharmaceuticals Corporation Common Stock made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3501 holding.
BlackRock Advisors first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2014 and has held it in 9 quarters since.
BlackRock Advisors's DMK Pharmaceuticals Corporation Common Stock position peaked at $30K in Q1 2016.
35 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.